Lexicon (LXRX) Q2 Revenue Soars 1,706%

Lexicon Pharmaceuticals (NASDAQ:LXRX), a biopharma company focused on developing treatments for diabetes, cardiovascular, and neurological diseases, released its second quarter 2025 financial results on August 6, 2025. The most important news: revenue (GAAP) reached $28.9 million in the second quarter of 2025, shattering consensus GAAP expectations of $4.87 million, with most of this coming from a significant licensing payment by Novo Nordisk. Earnings per share (GAAP) came in at $0.01, a dramatic swing from analyst forecasts of a GAAP loss and a substantial turnaround from the previous year's GAAP loss of $0.17 per share in the second quarter of 2024. While the quarter showed a rare net profit (GAAP) and dramatic cuts in research and administrative costs, these headline gains stemmed primarily from a one-time event. Core business sales were subdued, raising questions about the underlying commercial strength. Source: Analyst estimates for the quarter provided by FactSet. Lexicon Pharmaceuticals specializes in the discovery, development, and commercialization of innovative drugs for conditions such as diabetic peripheral neuropathic pain, obesity, and heart failure. Its drug portfolio includes pilavapadin (an oral, non-opioid pain medication); LX9851 (an oral treatment for obesity and metabolic diseases); and sotagliflozin (marketed as INPEFA for heart failure, with ongoing trials for other uses).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool